DE60144554D1 - Blockade von spannungabhängigen natriumkanälen - Google Patents

Blockade von spannungabhängigen natriumkanälen

Info

Publication number
DE60144554D1
DE60144554D1 DE60144554T DE60144554T DE60144554D1 DE 60144554 D1 DE60144554 D1 DE 60144554D1 DE 60144554 T DE60144554 T DE 60144554T DE 60144554 T DE60144554 T DE 60144554T DE 60144554 D1 DE60144554 D1 DE 60144554D1
Authority
DE
Germany
Prior art keywords
sodium channels
blockade
dependent sodium
voltage dependent
voltage
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60144554T
Other languages
English (en)
Inventor
G Garthwaite
D Selwood
M Kling
G Wishart
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UCL Business Ltd
Original Assignee
UCL Business Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by UCL Business Ltd filed Critical UCL Business Ltd
Application granted granted Critical
Publication of DE60144554D1 publication Critical patent/DE60144554D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • A61K31/41551,2-Diazoles non condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • A61K31/4161,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • A61K31/422Oxazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE60144554T 2000-02-04 2001-02-05 Blockade von spannungabhängigen natriumkanälen Expired - Lifetime DE60144554D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0002666.6A GB0002666D0 (en) 2000-02-04 2000-02-04 Blockade of voltage dependent sodium channels
PCT/GB2001/000472 WO2001057024A1 (en) 2000-02-04 2001-02-05 Blockade of voltage dependent sodium channels

Publications (1)

Publication Number Publication Date
DE60144554D1 true DE60144554D1 (de) 2011-06-16

Family

ID=9885029

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60144554T Expired - Lifetime DE60144554D1 (de) 2000-02-04 2001-02-05 Blockade von spannungabhängigen natriumkanälen

Country Status (8)

Country Link
US (2) US7009056B2 (de)
EP (1) EP1252156B1 (de)
AT (1) ATE508127T1 (de)
AU (1) AU2001232002A1 (de)
DE (1) DE60144554D1 (de)
ES (1) ES2362859T3 (de)
GB (1) GB0002666D0 (de)
WO (1) WO2001057024A1 (de)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090324721A1 (en) 1996-09-23 2009-12-31 Jack Kennedy Hydrogels Suitable For Use In Polyp Removal
AR032653A1 (es) * 2001-02-09 2003-11-19 Telik Inc Inhibidores heterociclicos del trasportador de glicina 2 composiciones farmaceuticas, uso y metodos.
ATE449763T1 (de) 2001-04-16 2009-12-15 Eisai R&D Man Co Ltd 1h-indazolverbindungen die jnk hemmen
GB0120238D0 (en) * 2001-08-20 2001-10-10 Univ College Of London Sodium channel regulators and modulators
US20040077702A1 (en) * 2001-09-14 2004-04-22 Wen-Mei Fu Treatment of nuerodegenerative diseases
DE10149370A1 (de) * 2001-10-06 2003-04-10 Merck Patent Gmbh Pyrazolderivate
WO2003037900A2 (en) * 2001-11-01 2003-05-08 Icagen, Inc. Pyrazolopyrimidines
TWI264304B (en) * 2002-01-25 2006-10-21 Yung Shin Pharm Ind Co Ltd Methods of treating sepsis
US20050209252A1 (en) * 2002-03-29 2005-09-22 Che-Ming Teng Cancer treatment
US7166293B2 (en) * 2002-03-29 2007-01-23 Carlsbad Technology, Inc. Angiogenesis inhibitors
DE10216145A1 (de) * 2002-04-12 2003-10-23 Bayer Ag Verwendung von Stimulatoren der löslichen Guanylatcyclase zur Behandlung von Glaukom
US20050119278A1 (en) * 2002-05-16 2005-06-02 Che-Ming Teng Anti-angiogenesis methods
CN100436445C (zh) * 2003-02-07 2008-11-26 第一制药株式会社 吡唑衍生物
US20040220170A1 (en) * 2003-05-01 2004-11-04 Atkinson Robert N. Pyrazole-amides and sulfonamides as sodium channel modulators
WO2005030121A2 (en) * 2003-06-30 2005-04-07 Hif Bio, Inc. Compounds, compositions and methods
CN1832741A (zh) * 2003-08-07 2006-09-13 默克公司 作为11-β-羟甾类脱氢酶-1抑制剂的吡唑甲酰胺类
US6984652B2 (en) 2003-09-05 2006-01-10 Warner-Lambert Company Llc Gyrase inhibitors
US20070167499A1 (en) * 2003-10-27 2007-07-19 A*Bio Pte Ltd. Biaryl linked hydroxamates: preparation and pharmaceutical applications
US7663524B2 (en) * 2003-11-13 2010-02-16 Silicon Touch Technology Inc. Multi-channel display driver circuit incorporating modified D/A converters
TW200526641A (en) * 2003-12-26 2005-08-16 Daiichi Seiyaku Co Amidopyrazole derivatives
US7378532B2 (en) * 2004-03-26 2008-05-27 Yung Shin Pharmaceutical Ind. Co., Ltd. Fused pyrazolyl compound
US20080090836A1 (en) * 2004-09-20 2008-04-17 Peter Nilsson Pyrazole Compounds Useful In The Treatment Of Inflammation
WO2006032851A1 (en) 2004-09-20 2006-03-30 Biolipox Ab Pyrazole compounds useful in the treatment of inflammation
EP1647549A1 (de) 2004-10-14 2006-04-19 Laboratoire Theramex Indazole, Benzisoxazole und Benzisothiazole mit oestrogenen Eigenschaften
CA2588812A1 (en) 2004-11-29 2006-06-01 Warner-Lambert Company Llc Therapeutic pyrazolo[3,4-b] pyridines and indazoles
US7923465B2 (en) 2005-06-02 2011-04-12 Glenmark Pharmaceuticals S.A. Cannabinoid receptor ligands, pharmaceutical compositions containing them, and process for their preparation
JP5149003B2 (ja) 2005-06-21 2013-02-20 三井化学アグロ株式会社 アミド誘導体ならびに該化合物を含有する殺虫剤
TW200800911A (en) * 2005-10-20 2008-01-01 Biolipox Ab Pyrazoles useful in the treatment of inflammation
CN101300236A (zh) * 2005-10-31 2008-11-05 比奥里波克斯公司 作为脂肪加氧酶抑制剂的三唑化合物
TW200732320A (en) * 2005-10-31 2007-09-01 Biolipox Ab Pyrazoles useful in the treatment of inflammation
US20090088463A1 (en) * 2005-11-01 2009-04-02 Benjamin Pelcman Pyrazoles Useful in the Treatment of Inflammation
US8186555B2 (en) 2006-01-31 2012-05-29 Ethicon Endo-Surgery, Inc. Motor-driven surgical cutting and fastening instrument with mechanical closure system
DE102006020327A1 (de) * 2006-04-27 2007-12-27 Bayer Healthcare Ag Heterocyclisch substituierte, anellierte Pyrazol-Derivate und ihre Verwendung
DE102006021733A1 (de) * 2006-05-09 2007-11-22 Bayer Healthcare Ag 3-Tetrazolylindazole und 3-Tetrazolylpyrazolopyridine sowie ihre Verwendung
DE102006043443A1 (de) 2006-09-15 2008-03-27 Bayer Healthcare Ag Neue aza-bicyclische Verbindungen und ihre Verwendung
US7669747B2 (en) 2007-03-15 2010-03-02 Ethicon Endo-Surgery, Inc. Washer for use with a surgical stapling instrument
EA015952B1 (ru) * 2007-05-03 2011-12-30 Пфайзер Лимитед 2-пиридинкарбоксамидные производные в качестве модуляторов натриевых каналов
BRPI0812361A2 (pt) 2007-05-18 2015-02-03 Bayer Schering Pharma Ag Derivados de pirazol heteroaril-substituídos úteis parao tratamento de distúrbios e doenças hiperproliferativos associados à angiogênese
DE102008063992A1 (de) 2008-12-19 2010-09-02 Lerner, Zinoviy, Dipl.-Ing. Neue aliphatisch substituierte Pyrazolopyridine und ihre Verwendung
GB0917238D0 (en) 2009-10-01 2009-11-18 Univ London Blockade of voltage dependent sodium channels
US20110172428A1 (en) * 2010-01-12 2011-07-14 Shan-Ming Kuang Methods for the preparation of indazole-3-carboxylic acid and n-(s)-1-azabicyclo[2.2.2]oct-3-yl-1h-indazole-3-carboxamide hydrochloride salt
DE102010021637A1 (de) 2010-05-26 2011-12-01 Bayer Schering Pharma Aktiengesellschaft Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung
WO2011158108A2 (en) * 2010-06-16 2011-12-22 Purdue Pharma L.P. Aryl substituted indoles and the use thereof
US8921401B2 (en) 2013-02-07 2014-12-30 Musc Foundation For Research Development Pyrazole compounds, compositions and methods for treatment of degenerative diseases and disorders
AU2014220801A1 (en) 2013-02-21 2015-09-10 Adverio Pharma Gmbh Forms of methyl {4,6-diamino-2-[1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridino-3-yl]pyrimidino-5-yl}methyl carbamate
US10149680B2 (en) 2013-04-16 2018-12-11 Ethicon Llc Surgical instrument comprising a gap setting system
GB201511382D0 (en) 2015-06-29 2015-08-12 Imp Innovations Ltd Novel compounds and their use in therapy
EP3402780A1 (de) 2016-01-14 2018-11-21 Beth Israel Deaconess Medical Center, Inc. Mastzellenmodulatoren und verwendungen davon
CN110627767B (zh) * 2019-09-05 2020-08-25 中国药科大学 选择性丁酰胆碱酯酶抑制剂或其可药用的盐、其制备方法及用途
EP4213839A2 (de) * 2020-09-17 2023-07-26 Escient Pharmaceuticals, Inc. Modulatoren des mas-verwandten g-protein-rezeptors x4 sowie verwandte produkte und verfahren
WO2022263498A1 (en) * 2021-06-15 2022-12-22 Grünenthal GmbH Substituted pyrazole amides
CN113929627A (zh) * 2021-10-19 2022-01-14 吕梁学院 一种宾达利的合成方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2662692B1 (fr) 1990-05-30 1995-04-28 Novapharme Derives heterocycliques doues d'activite anticonvulsivante, procede de preparation et composition pharmaceutique.
US5795965A (en) 1991-04-25 1998-08-18 Chugai Seiyaku Kabushiki Kaisha Reshaped human to human interleukin-6 receptor
FR2714057B1 (fr) * 1993-12-17 1996-03-08 Sanofi Elf Nouveaux dérivés du 3-pyrazolecarboxamide, procédé pour leur préparation et compositions pharmaceutiques les contenant.
JP2928079B2 (ja) * 1994-02-14 1999-07-28 永信薬品工業股▲ふん▼有限公司 1−(置換ベンジル)−3−(置換アリール)縮合ピラゾール類、その製造法及びその用途
JPH11501623A (ja) 1995-03-02 1999-02-09 ファルマシア・アンド・アップジョン・カンパニー ピリミド[4,5−b]インドール
DE19642255A1 (de) * 1996-10-14 1998-04-16 Bayer Ag Verwendung von 1-Benzyl-3-(substituierten-hetaryl) -kondensierten Pyrazol-Derivaten
DE19642323A1 (de) 1996-10-14 1998-04-16 Bayer Ag Neue 1-Benzyl-3-(substituierte heteroaryl)-kondensierte Pyrazol-Derivate
DE19701277A1 (de) * 1997-01-16 1998-07-23 Bayer Ag Verfahren zur Herstellung von 1-Alkyl-pyrazol-5-carbonsäureestern
US5922746A (en) 1997-03-27 1999-07-13 Allergan Inhibition of noninactivating Na channels of mammalian optic nerve as a means of preventing optic nerve degeneration associated with glaucoma
US5877211A (en) 1997-11-21 1999-03-02 Allergan EP2 receptor agonists as neuroprotective agents for the eye
GB9726987D0 (en) 1997-12-22 1998-02-18 Glaxo Group Ltd Compounds
AU754681B2 (en) 1998-02-04 2002-11-21 Euro-Celtique S.A. Substituted semicarbazides and the use thereof
DE19834714A1 (de) 1998-07-31 2000-02-03 Boehringer Ingelheim Pharma Neue 2,3,3a,4,9,9a-Hexahydro-8-hydroxy-1H-ben[f]indole, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US6509367B1 (en) * 2001-09-22 2003-01-21 Virginia Commonwealth University Pyrazole cannabinoid agonist and antagonists

Also Published As

Publication number Publication date
ATE508127T1 (de) 2011-05-15
US7790761B2 (en) 2010-09-07
US7009056B2 (en) 2006-03-07
US20030171403A1 (en) 2003-09-11
WO2001057024A1 (en) 2001-08-09
AU2001232002A1 (en) 2001-08-14
EP1252156A1 (de) 2002-10-30
GB0002666D0 (en) 2000-03-29
US20060100248A1 (en) 2006-05-11
ES2362859T3 (es) 2011-07-14
EP1252156B1 (de) 2011-05-04

Similar Documents

Publication Publication Date Title
ATE508127T1 (de) Blockade von spannungabhängigen natriumkanälen
NZ324887A (en) Piperazine and piperidine compounds with analgesic effect
SE0101387D0 (sv) Novel compounds
SE9900961D0 (sv) Novel compounds
CY1106606T1 (el) Διϋδροξυπυριμιδινο καρβοξαμιδια αναστολεις της ιντεγκρασης του hiv
EP1248612A4 (de) Neue substanzen und verbindungen als protease-inhibitoren
ATE348826T1 (de) Aminopiperidin chinoline und ihre azaisosteren analoga mit antibakterieller wirkung
TR200201874T2 (tr) Proteaz inhibitörleri olarak yeni bileşikler ve bileşimler.
CY1106952T1 (el) Ηλεκτρικο αλας της ο-απομεθυλ-βενλαφαξινης
RS50031B (sr) Triciklični inhibitori poli(adp-riboza)polimeraza
DK0977741T3 (da) Substituerede phenylderivater, deres fremstilling og anvendelse
TR200200579T2 (tr) Amino-tirazolpiridin türevleri.
DE69105501D1 (de) (+)-alpha-(2,3 dimethoxyphenyl)-1-[2-(fluorophenyl)ethyl]-4-piperidinmethanol.
UY26082A1 (es) Derivados de 1,4-diazabiciclo [3.2.2] nonan-4-carboxilato y -carboxamidas, su preparacion y su aplicacion en terapeutica
ATE303384T1 (de) 1-biaryl-1,8-naphthyridin-4-one als phosphodieseterase-inhibitoren
SE9802206D0 (sv) Novel compounds
SE0300908D0 (sv) Azaindole derivatives, preparations thereof, uses thereof and compositions containing them
ATE325135T1 (de) 2-alkylierte cyclodextrinderivate : umkehrungsmittel von medikament-induzierter neuromuskulärer blockierung
AU2001290480A1 (en) Cyclized benzamide neurokinin antagonists for use in therapy
SE9902267D0 (sv) New compounds
DE60112960D1 (de) Kondensierte pyridoindolderivate
ATE333457T1 (de) Zyklische gmp-spezifische phosphodiesteraseinhibitoren
SE9802209D0 (sv) Novel compounds
ATE253359T1 (de) Antithrombotische mittel
TR200001909T2 (tr) Matris metaloprotez inhibitörleri.